Kura Oncology (KURA) Q3 2024 earnings summary

Executive summary

• Advancing a pipeline of novel targeted therapies for oncology, focusing on menin and farnesyl transferase inhibitors, with ziftomenib showing strong safety and efficacy in AML and receiving FDA Breakthrough Therapy Designation for R/R NPM1-mutant AML; pivotal trial enrollment is complete and topline results are expected in early 2025.

• Expansion into solid tumors (GIST) and diabetes is underway, supported by preclinical data and next-generation candidate nomination planned for 1H 2025.

• Strategic collaborations with Bristol Myers Squibb, Novartis, and Mirati to expand clinical development and combination studies.

• KO-2806 and tipifarnib are advancing in clinical trials, with KO-2806 in phase 1 dose-escalation for solid tumors and tipifarnib in PIK3CA-dependent HNSCC.

• Robust financial position with $455.3M in cash as of September 30, 2024, providing runway into 2027.

Financial highlights

• Q3 2024 R&D expenses were $41.7M, up from $29.3M in Q3 2023, mainly due to increased clinical trial costs.

• General and administrative expenses rose to $18.2M from $13.1M year-over-year.

• Net loss for Q3 2024 was $54.4M, compared to $38.6M in Q3 2023, including $8.3M in non-cash share-based compensation.

• Cash, cash equivalents, and short-term investments totaled $455.3M as of September 30, 2024, up from $424M at year-end 2023.

• Net proceeds of $145.8M were raised in a January 2024 private placement; no shares sold under the $150M ATM facility as of September 30, 2024.

Outlook and guidance

• Cash runway is expected to fund operations into 2027 based on current plans.

• Topline results from the pivotal/Phase 2 KOMET-001 trial in NPM1-mutant AML expected in early 2025, with NDA submission planned within months after data lock.

• Updated data from KOMET-007 and other ziftomenib combination trials to be presented at ASH 2024 and in 2025.

• Proof-of-concept study for ziftomenib in GIST and nomination of next-gen menin inhibitor for diabetes planned for 1H 2025.

• Expansion cohorts for KO-2806 and KURRENT-HN/cabozantinib trials expected in 1H 2025.